ANNOUNCING MGC PHARMACEUTICALS AS A SILVER PARTNER FOR CANNABIS EUROPA LONDON

ANNOUNCING MGC PHARMACEUTICALS AS A SILVER PARTNER FOR CANNABIS EUROPA LONDON

Cannabis Europa is excited to announce MGC Pharmaceuticals as a Silver Partner for our London conference this June at the Southbank Centre. MGC Pharmaceuticals (ASX:MXC, OTC US: MGCLF) is an EU based bio-pharma company, creating a seamless pipeline of high quality, pharmaceutical grade products, taking advantage of the medical value of phytocannabinoids. MGC Pharma’s goal is to facilitate the transformation of phytocannabinoids into true medicinal product pipelines, and to provide breakthrough solutions for prevalent global health issues to improve the quality of patients’ lives. Cannabis Europa is the foremost arena to share knowledge and shape the future of medical cannabis...

HEALTH-TECH AND BIG DATA: SHAPING THE MODERN CANNABIS INDUSTRY

HEALTH-TECH AND BIG DATA: SHAPING THE MODERN CANNABIS INDUSTRY

Medical cannabis has the opportunity to be the first modern medical industry that is built with a digital-first approach. Technology is already providing ways to educate people, empower patients, fuel innovation and feedback into the product development cycle. For example, while governments struggle to develop the infrastructure for a medical cannabis industry – or indeed even drag their feet in terms of acknowledging the medical benefits of cannabis-based products – the Internet can provide information and education. In the UK, patients are struggling to access medical cannabis partly due to a lack of training and knowledge in the medical community...

CBD AND SPORT: PERMEATING THE MAINSTREAM

CBD AND SPORT: PERMEATING THE MAINSTREAM

As CBD has permeated popular consciousness, athletes across the world have shared stories about how they use CBD and cannabis products as part of their training and recovery. As sales and popularity soar, consumers and brands are pushing regulators to keep up with the industry. In January 2018, cannabidiol (commonly known as CBD) was removed from the World Anti-Doping Agency’s (WADA) list of banned substances. WADA, led by the International Olympic Committee (IOC), is responsible for the World Anti-Doping Code which aims to harmonise anti-doping regulations in all sports and countries. It has been adopted by more than 600 sports...

ANNOUNCING HEXO CORP. AS A BRONZE PARTNER FOR CANNABIS EUROPA LONDON

ANNOUNCING HEXO CORP. AS A BRONZE PARTNER FOR CANNABIS EUROPA LONDON

Cannabis Europa is excited to announce HEXO as a bronze partner for our London conference this June at Southbank Centre. HEXO Corp is an award-winning Canadian medical and adult-use cannabis company and home to Elixir CBD – winner of Innovation of the Year and Cannabis Product of the Year (2018 Canadian Cannabis Awards). “Cannabis Europa is a unique and forward-thinking opportunity for the emerging EU cannabis industry and the established Canadian industry to gather, share and learn from each other. HEXO is very excited to join the conversation and support this wonderful event.” — HEXO TEAM Cannabis Europa is proud...

ANNOUNCING MEMERY CRYSTAL AS A SILVER PARTNER FOR CANNABIS EUROPA LONDON

ANNOUNCING MEMERY CRYSTAL AS A SILVER PARTNER FOR CANNABIS EUROPA LONDON

Cannabis Europa is excited to announce Memery Crystal as a Silver Partner for our London conference this June at the Southbank Centre. Memery Crystal is the leading UK law firm in the cannabis sector, advising on business set-up, capital markets, mergers and acquisitions, private fundraising, licensing and commercial contracts. “We are looking forward to attending the event and sharing our expertise with like-minded organisations and individuals from across Europe,” says Simon Bastin, Business Development Director. At the Forefront Cannabis Europa is Europe’s premier medical cannabis conference and the foremost arena to share knowledge and shape the future of the industry...

TWELVE MONTHS IN MEDICAL CANNABIS

TWELVE MONTHS IN MEDICAL CANNABIS

One year on since the inaugural Cannabis Europa in London, the landscape of the European cannabis industry has changed dramatically. This time 12 months ago, medical cannabis was still illegal in the UK, Belgium, Luxembourg, Portugal and Greece despite growing momentum behind legalisation campaigns. A YEAR IN REVIEW On 21st-22nd May 2018, over 400 industry insiders gathered at Europe’s premier medical cannabis conference to discuss the future of medical cannabis in Europe. Patients, doctors, researchers, politicians, policymakers and entrepreneurs from around the world gathered at the Barbican in London to attend the first ever Cannabis Europa. There were a number...

THE VALUE OF BEING A FIRST MOVER IN CANNABIS

THE VALUE OF BEING A FIRST MOVER IN CANNABIS

Right now, the cannabis industry is so new that being a part of it makes you a first mover by default. The paradox of being a first mover is that by definition you pave the way. Your costs are going to be higher and your resources more thinly spread. They make, and pay for, the mistakes that others witness and navigate around. In 2001, Canada became the first country in the world to legalise medical cannabis. Seventeen years later, they became the second country in the world to legalise recreational cannabis. While much of the international cannabis community heralded the...

ANNOUNCING EMMAC LIFE SCIENCES AS A SILVER PARTNER FOR CANNABIS EUROPA LONDON

ANNOUNCING EMMAC LIFE SCIENCES AS A SILVER PARTNER FOR CANNABIS EUROPA LONDON

Cannabis Europa is excited to announce EMMAC Life Sciences as a Silver Partner for our London conference this June at the Southbank Centre. EMMAC Life Sciences is an independent European medical cannabis company, combining the latest science and research with cutting-edge cultivation, extraction and production. Spearheading Relief for UK Patients This April, EMMAC announced the acquisition of Rokshaw, a leading UK Specials manufacturer, enabling the company to import medical cannabis into the UK to meet the growing demand for premium medical cannabis products. EMMAC aims to close the gap between cannabis policy reform and the subsequent lack of patients access...

ANNOUNCING AURORA AS THE HEADLINE PARTNER FOR CANNABIS EUROPA LONDON

ANNOUNCING AURORA AS THE HEADLINE PARTNER FOR CANNABIS EUROPA LONDON

Cannabis Europa is excited to announce Aurora as the Headline Partner for our London conference this June at the Southbank Centre. With operations in 24 countries, Aurora is at the forefront of the growing global medical cannabis industry. Aurora was an early entrant into the European market, supplying patients in Germany with high-quality medical cannabis since 2015. Aurora Europe, along with its subsidiary Aurora Deutschland, is now the largest authorised importer, exporter, and distributor of EU-GMP certified medical cannabis in the European Union. This footprint continues to grow, with Aurora’s recent public tender win in Germany, enabling the Company to...

HOW CLOSE IS EUROPEAN HARMONISATION ON MEDICAL CANNABIS?

HOW CLOSE IS EUROPEAN HARMONISATION ON MEDICAL CANNABIS?

On the face of it, the European medical cannabis scene looks rosy – people often state that over 20 EU countries have legalised medical cannabis in some form or another. Dig a little deeper and you discover in many cases ‘some form or another’ can be a far cry from what a patient actually needs. According to MJBiz Daily, once you exclude Sativex or synthetic cannabinoids, only three countries in Europe – Germany, Italy and the Netherlands – have any meaningful sales of medical cannabis. Depending on where you live in Europe, being a medical cannabis patient – or someone...

ANNOUNCING SHIMADZU EUROPE AS A SILVER PARTNER FOR CANNABIS EUROPA LONDON

ANNOUNCING SHIMADZU EUROPE AS A SILVER PARTNER FOR CANNABIS EUROPA LONDON

Cannabis Europa is excited to announce Shimadzu Europe as a silver partner for the London conference on June 24th and 25th at the Southbank Centre. Shimadzu is a medical equipment producer specialising in analytical instruments. The company develops cannabis testing solutions, such as potency testing and terpene profiling. “We are looking forward to Cannabis Europa in London to see where we can support people in their efforts and find possibilities for collaboration.” Dr Gesa Schad, Product Manager at Shimadzu Europa Tradition of Quality Shimadzu Europe are industry leaders in analytical chemistry and life sciences, demonstrating a history of embracing new...

BLURRING BOUNDARIES: THE EVOLUTION OF CBD

BLURRING BOUNDARIES: THE EVOLUTION OF CBD

In recent years, cannabidiol (commonly known as CBD) products have soared in popularity in the UK and across Europe, spurred on by claims made about their medical benefits. While CBD is being touted as a potential treatment for a spectrum of different conditions, manufacturers are utilising the compound as an add-on to a whole range of fast-moving consumer goods (FMCG) products – blurring the line between medical, wellness and recreational. CBD, in its pharmaceutical form, has been approved for medical use. Epidiolex, for example, is prescribed as a treatment for severe epilepsy (Dravet and Lennox-Gastaut syndrome) and there is promising...

ANNOUNCING ZENABIS AS OUR BRONZE PARTNER FOR CANNABIS EUROPA LONDON 2019

ANNOUNCING ZENABIS AS OUR BRONZE PARTNER FOR CANNABIS EUROPA LONDON 2019

Cannabis Europa is proud to announce Zenabis as a Bronze Partner for Cannabis Europa London on June 24th-25th. Zenabis is a significant licensed cannabis cultivator of medical and recreational cannabis in Canada, employing staff coast-to-coast, across facilities in New Brunswick, British Columbia and Nova Scotia. In addition to gaining technologically advanced knowledge of plant propagation, the recent addition of state of the art greenhouses in Langley, British Columbia provides Zenabis with 3.5 million square feet of facility space that can, upon full conversion, be dedicated to cannabis production space. The London conference on June 24th and 25th will be a...

ANNOUNCING BEDROCAN AS SILVER PARTNER OF CANNABIS EUROPA LONDON 2019

ANNOUNCING BEDROCAN AS SILVER PARTNER OF CANNABIS EUROPA LONDON 2019

Cannabis Europa is pleased to introduce Bedrocan as a Silver Partner for the London conference on the June 24th-25th at the Southbank Centre. Since 2003, Bedrocan has been producing standardised cannabis of pharmaceutical quality for the Dutch government. It’s the oldest legal cannabis company in the world, providing several chemically different cannabis varieties for prescription and for raw materials for the pharmaceutical industry (API). Bedrocan CEO Tjalling Erkelens speaking at the inaugural Cannabis Europa in London. “When it comes to medicinal cannabis,” says founder and CEO Tjalling Erkelens, “The world is changing. And it’s changing fast. Now that the EU,...

A HISTORIC MOMENT FOR EUROPEAN MEDICAL CANNABIS

A HISTORIC MOMENT FOR EUROPEAN MEDICAL CANNABIS

Cannabis Europa brought international stakeholders, fresh perspectives and stimulating discussion to Paris to drive forward Europe’s burgeoning medical cannabis space. On February 8th, Cannabis Europa was proud to host our first French conference, at Paris’ Maison de la Chimie. This world-renowned scientific institution, just steps from the Assemblée Nationale, is known for its commitment to partnering top-level scientists with decision-makers to foster science-based solutions for society. After a sparkling Welcome Reception the evening before, the full-day conference featured a series of deep dives into the complex regulatory landscape, groundbreaking scientific research, and the technical and business expertise that gives the...

A BIG THANKS TO CANACCORD GENUITY FOR HOSTING WELCOME DRINKS FOR CANNABIS EUROPA PARIS

A BIG THANKS TO CANACCORD GENUITY FOR HOSTING WELCOME DRINKS FOR CANNABIS EUROPA PARIS

Cannabis Europa wants to thank Canaccord Genuity for hosting the welcome drinks reception for our Paris conference. Alex Brooks, Senior Analyst at Canacord Genuity, will be speaking on the the Cannabis Capital panel. Through its principal subsidiaries, Canaccord Genuity is a leading independent, full-service financial services firm, with operations in two principal segments of the securities industry -: wealth management and capital markets. Since its establishment in 1950, the Company has been driven by an unwavering commitment to building lasting client relationships. We achieve this by generating value for our individual, institutional and corporate clients through comprehensive investment solutions, brokerage...

PANEL LINEUP – PHARMA FUTURES

PANEL LINEUP – PHARMA FUTURES

PHARMA FUTURES PETIT AMPITHEATER 12:35-13:35 Do France’s strong hemp and pharmaceutical industries give it a competitive edge in medical cannabis production? Is greater collaboration between international medical cannabis producers and the pharmaceutical giants in Europe needed to further legitimise the development of the industry? How will biosynthesis impact the production of cannabinoid medicines? What are the benefits of full spectrum products versus extracts/isolated compound products? To what extent are patents applicable to phytocannabinoids? CHAIR: Sofia Sanz With more than 10 years expertise in the healthcare Industry, Sofia Sanz worked as Business Development & Sales Manager at Alcaliber, a world leading...

PANEL LINEUP – IN CONVERSATION

PANEL LINEUP – IN CONVERSATION

IN CONVERSATION PETIT AMPITHEATER 15:45-16:45 CHAIR: Laura Jane Gautier Laura-Jane Gautier is a journalist and panel moderator. She started her carrier on several French TV Shows and later worked in different news channels, with a focus on economics. For two years she’s been doing daily interviews of CEOs, startups, lawyers and media personnel. Today Laura-Jane is a self-employed journalist and moderates panels on topics such as digital transformation, tech, public policies, politics, social business or artificial intelligence. Bernard Kouchner Bernard Kouchner is a French doctor and politician, co-founder of Médecins Sans Frontières and Médecins du Monde, and former Minister from...

PANEL LINEUP – POLITICAL SUBSTANCE

PANEL LINEUP – POLITICAL SUBSTANCE

POLITICAL SUBSTANCE (FR) PETIT AMPITHEATER 10:15-11:15 French and Canadian politicians join medical professionals and regulators to break down the issues, goals and hindrances surrounding medical cannabis regulation in France. CHAIR: Pierre-Yves Geoffard Pierre-Yves Geoffard is a French economist specialising in health economics. He has been director of the Paris School of Economics since 2013, director of studies at EHESS since 2008 and director of research at CNRS since 2003. He also writes an economic column in the newspaper Libération. Olivir Véran Olivir Véran is a neurologist at the Grenoble Hospital and MP for La République En Marche. After the publication...

PANEL LINEUP – LOCAL GLOBAL

PANEL LINEUP – LOCAL GLOBAL

LOCAL GLOBAL (FR) EUROPA STAGE – 15:45-16:45 What impact would a European Parliament resolution to regulate medical cannabis have on member states? What is the role of each level of government in promoting and ensuring responsible drug policy reform? How can we facilitate the sharing of knowledge and best practice between policy makers in Europe? How will the outcome of the WHO’s review into the international scheduling of cannabis affect government stances on the drug in Europe and worldwide? Could France’s regulation of medical cannabis (alongside Germany and the UK) ‘tip the scales’ of medical cannabis access in Europe? With...